For over a century, institutions like Somerset Medical Center have served as cornerstones of community health, providing medical services and health education to the public. This legacy of general health information dissemination has long focused on broad wellness topics, preventive care, and the safe use of common treatments. Within this framework, patients have historically been informed about medications in a general context, emphasizing benefits and typical side effects without delving into specific, long-term risks associated with particular drug classes. As the understanding of pharmaceutical effects has evolved, the focus has shifted from general health guidance to more targeted occupational and clinical exposure concerns. One notable area of transition involves the medication metoclopramide, commonly known by the brand name Reglan. Originally prescribed for gastrointestinal motility disorders, its widespread use has prompted a closer examination of prolonged exposure risks. Specifically, the connection between Reglan use and the development of tardive dyskinesia—a condition involving involuntary, repetitive movements—has become a significant point of scrutiny. This shift moves the conversation from general health maintenance to a more precise concern: the risk associated with cumulative exposure to this particular drug. Consequently, the criteria for legal settlements in Reglan-related tardive dyskinesia cases now center on establishing a clear history of exposure and the subsequent manifestation of symptoms, marking a departure from broad health education into focused, exposure-based risk assessment.
Reglan (metoclopramide) is a dopamine receptor blocking agent prescribed for conditions such as diabetic gastroparesis and symptomatic gastroesophageal reflux. Its use carries a well-documented risk of tardive dyskinesia (TD), a potentially irreversible hyperkinetic movement disorder. The U.S. Food and Drug Administration (FDA) requires a boxed warning on Reglan labeling, stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further advises that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia is characterized by involuntary, often disfiguring movements of the face, tongue, trunk, or extremities. The condition is caused by exposure to dopamine receptor blocking agents, including metoclopramide, and may be partially suppressed by the drug itself, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Although TD was initially associated primarily with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Increased prescribing of these agents, along with low rates of remission, has contributed to a rising prevalence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). Treatment options include VMAT2 inhibitors, which have been FDA-approved for TD based on clinical trials (https://pubmed.ncbi.nlm.nih.gov/29433808/). The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the striatum, leading to upregulation and supersensitivity of these receptors, which in turn produces the hyperkinetic movements characteristic of TD. This process is dose- and duration-dependent, with higher cumulative exposure increasing risk. The FDA label emphasizes that metoclopramide can cause TD and that the risk increases with treatment duration and total dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, the drug may suppress or partially suppress signs of TD, masking the underlying disease process and delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Risk factors for developing TD from metoclopramide include elderly age, female sex, diabetes, liver or kidney failure, and concomitant use of antipsychotic drugs, which lower the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). Data suggest that the risk of TD from metoclopramide is low, in the range of 0.1% per 1000 patient-years, which is far below previously estimated risks of 1% to 10% cited in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, because TD can be irreversible and severely disabling, even a low risk is clinically significant, particularly in vulnerable populations.
Adequacy of warnings regarding Reglan and TD has been a central issue in litigation. The FDA-mandated boxed warning explicitly states that metoclopramide can cause TD, that the risk increases with duration and dosage, and that the drug is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also instructs prescribers to use Reglan for the shortest duration and to immediately discontinue it if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring or early discontinuation. Settlement-related considerations for affected patients typically involve demonstrating that the drug was used beyond recommended durations, that TD developed as a result, and that warnings were insufficient to prevent harm. The timeline between exposure and documented harm is critical: TD often emerges after months or years of continuous use, and symptoms may persist or worsen even after drug cessation. The FDA label advises that metoclopramide may suppress TD signs, so diagnosis may be delayed until after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Reglan-associated tardive dyskinesia is a serious, potentially irreversible movement disorder linked to dopamine receptor blockade. Risk is dose- and duration-dependent, with higher vulnerability in elderly females, diabetics, and those with renal or hepatic impairment. FDA warnings mandate limited treatment duration and prompt discontinuation upon symptom emergence. For patients who develop TD after prolonged Reglan use, settlement criteria often hinge on evidence of extended exposure, inadequate monitoring, and failure to heed label warnings. The condition remains a significant public health concern, with rising prevalence due to widespread use of dopamine blocking agents and limited remission rates.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. It is caused by exposure to dopamine receptor blocking agents like Reglan (metoclopramide). The risk increases with longer treatment duration and higher cumulative dosage, as noted in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Settlement criteria typically require evidence of prolonged Reglan use beyond recommended durations, a confirmed diagnosis of tardive dyskinesia, and proof that the drug's warnings were inadequate to prevent harm. The FDA label advises using Reglan for the shortest duration necessary and discontinuing if TD symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Data suggest the risk of TD from metoclopramide is low, around 0.1% per 1000 patient-years, which is lower than earlier estimates of 1-10% (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, because TD can be severe and irreversible, even a low risk is clinically significant, especially in vulnerable populations like the elderly and diabetics.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.